Company Overview and News
Novocure strengthened its Board of Directors and Abeona Therapeutics received a key analyst thumbs up. Two possible trades are suggested.
SGEN NKTR DCPH ATRS NVCR PTLA LOXO CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE BMY MOR EXEL BLUE XNCR INCY NBIX GLPG ABEO AKCA HCM HCM ADMS GSK JNCE MRK IONS NVS ABEOW ARRY
atrs-8k_20180605.htm UNITED STATES
FDA Commissioner Scott Gottlieb´s remarks concerning the potential of gene therapy, bode well for stocks participating in that theme.
SGEN NKTR ATRS BLCM VRTX NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN GSK BLUE RDUS BMY CALD MOR EXEL GILD BLUE XNCR SLDB NBIX CRSP GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY
Back in early January my article "3 Biotechs For The January Effect" was published. The article highlighted Geron (GERN), Antares Pharma (ATRS) and AcelRX (ACRX). This article is to assess my picks so far in May and outline prospects going forward to determine if we should sell, hold or buy more. Thus far, all three well overperformed both the Nasdaq (QQQ) as well as their small biotech (SBIO) peer group.
EWING, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (“Antares”) (“The Company”) today announced that it has received $4.75 million from Ferring Pharmaceuticals (“Ferring”) in connection with the previously disclosed sale of Antares’ worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto injector device to Ferring. The purchase price of up to $14.
ATRS AMAG TEVJF TEVA TEVVF
My ¨Week in Review¨ blog post appears to have the makings of a permanent feature due to positive feedback received thus far.
SGEN SCD NKTR ATRS NVCR PTLA CORT ONCE BPMC HNCMF DVAX BIIB ALXN FCSC CELG GSK BLUE RDUS BMY EXEL BLUE XNCR SM NBIX GLPG ABEO HCM HCM ADMS GSK MRK IONS NVS ABEOW ARRY
atrs-8k_20180509.htm UNITED STATES
atrs-10q_20180331.htm UNITED STATES
The following slide deck was published by Antares Pharma Inc. in conjunction with their 2018 Q1 earnings call.
atrs-8k_20180508.htm UNITED STATES
EWING, N.J., May 08, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the Company) today reported operating and financial results for the first quarter ended March 31, 2018. The Company reported revenue of $12.7 million and a net loss per share of $0.04 for the quarter ended March 31, 2018.
ATRS AMAG TEVJF TEVA TEVVF
The M&A theme appears set to continue in the spotlight this year, with Gilead to put cash to work and Takeda likely to come to terms with Shire.
SGEN ATRS NKTR APA MTSI DB NVCR PTLA CORT ONCE BPMC HNCMF DVAX ALXN GSK BLUE RDUS EXEL GILD BLUE XNCR SLDB NBIX GLPG ABEO HCM HCM ADMS GSK IONS NVS ABEOW ARRY
2017-10-31 - Asif
Antares Pharma, Inc. is an emerging, specialty pharmaceutical company that focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its strategy is to identify new or existing approved drug formulations and apply its drug delivery technology to enhance the drug compounds and delivery methods. The company develop, manufacture and commercialize, for itself or with partners, novel therapeutic products using its advanced drug delivery systems that are designed to help improve safety and efficacy, reduce side effects, and enhance patient comfort and adherence. Its subcutaneous injection technology platforms include the VIBEX® pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-dose pen injectors for use with standard cartridges. Antares Pharma has a portfolio of proprietary and partnered pro...
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET